The EC Grants Yescarta Marketing Authorization in 2L LBCL
On Monday, October 17, Gilead (Kite) announced (press release) that the European Commission (EC) has granted Yescarta approval (CD19 CAR-T) for the treatment of DLBCL and high-grade B-cell lymphoma (HGBL) refractory patients or that have relapsed within 12 months of 1L chemoimmunotherapy (2L LBCL). Below, Celltelligence provides insights on Yescarta’s approval in the EU, while comparing it with key competitor Breyanzi (BMS’s CD19 CAR-T).
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.